Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Butyric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL28426761 | 0.97 | FFAR3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL28456519 | 0.97 | FFAR3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL27933618 | 0.88 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL3824915 | 0.88 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL27791395 | 0.86 | FFAR3 (0.77) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL18653501 | 0.86 | FFAR3 (0.77) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL11745812 | 0.85 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL611372 | 0.85 | — | — | |
| Butyric Acid SCHEMBL15610536 | 0.85 | — | — | |
| Butyric Acid SCHEMBL27418636 | 0.85 | FFAR3 (0.87) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017205828-A1 | GUANIDINIUM-BASED IONIC LIQUIDS IN ABSORPTION CHILLERS | YAZAKI CORPORATION (JP) | 2017-11-30 | — | — | WO | claimed |
| US-8278309-B2 | Synthetic mimetics of host defense and uses thereof | POLYMEDIX, INC. (US) | 2012-10-02 | — | — | US | claimed |
| EP-2358380-A1 | SYNTHETIC MIMETICS OF HOST DEFENSE AND USES THEREOF | Polymedix, Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010062573-A1 | SYNTHETIC MIMETICS OF HOST DEFENSE AND USES THEREOF | POLYMEDIX, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| US-12491493-B1 | Amine appended bimetallic metal-organic framework (MOF-74) for carbon dioxide capture and method of preparation thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-12-09 | — | — | US | disclosed |
| CN-118139636-A | Delivery of promoted concentrated antibody formulations using hyaluronidase | 武田药品工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| CN-111621267-B | Environment-friendly hyperbranched poly-guano acid shale intercalation inhibitor | 西南石油大学 | 2022-04-01 | — | — | CN | disclosed |
| CN-112029769-B | Construction method of Cyp1a1 gene knockout mouse model and application of model in sepsis | 中国人民解放军陆军特色医学中心 | 2022-03-22 | — | — | CN | disclosed |
| CN-112920065-A | Benzil compound and preparation method and application thereof | 上海中医药大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-112029769-A | Construction method of Cyp1a1 gene knockout mouse model and application of model in sepsis | 中国人民解放军陆军特色医学中心 | 2020-12-04 | — | — | CN | disclosed |
| CN-111621267-A | Environment-friendly hyperbranched poly-guano acid shale intercalation inhibitor | 西南石油大学 | 2020-09-04 | — | — | CN | disclosed |
| WO-2017205807-A1 | EUTECTIC MIXTURES OF IONIC LIQUIDS IN ABSORPTION CHILLERS | YAZAKI CORPORATION (JP) | 2017-11-30 | — | — | WO | disclosed |
| WO-2010059498-A2 | DYE SENSITIZED PHOTOVOLTAIC CELL | KONARKA TECHNOLOGIES, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100105703-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | POLYMEDIX, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| CN-100519519-C | Agmatine derivative and medicament usage thereof | INST PHARM & TOXICOLOGY AMMS (CN) | 2009-07-29 | — | — | CN | disclosed |
| US-20090032286-A1 | Epoxy Resin Composition | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101151294-A | Epoxy resin composition | ASAHI CHEMICAL CORP (JP) | 2008-03-26 | — | — | CN | disclosed |
| EP-1867672-A1 | EPOXY RESIN COMPOSITION | Asahi Kasei Chemicals Corporation (JP) | 2007-12-19 | — | — | EP | disclosed |
| CN-101062907-A | Agmatine derivative and medicament usage thereof | POISON MED INST PLA MED ACAD (CN) | 2007-10-31 | — | — | CN | disclosed |
| CN-1834085-A | Trilerium and trilerium marked agmatine and application in biochemistry and medicine research | INST OF TOXIC & MEDICINES A M (CN) | 2006-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105703-A1 | Synthetic Mimetics Of Host Defense And Uses Thereof | TLR3, MYD88, TLR5 | FFAR3 1661/4885HDAC3 2101/4885HDAC1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.